Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rakesh Ranjan

Psychiatry Medina, OH Medical Doctor

NPI 1073549606 CMS profile 849105

801 E Washington St, Suite 150, Medina, OH 44256

Open in the dashboard

General payments

$423,495

1,339 records reported · program years 2019–2025

Research payments

$1,685

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$290,080 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Rakesh Ranjan of Medina, OH is reported in the CMS Open Payments database as having received $423,495 across 1,339 general payments and $1,685 in research payments paid to them. Separately, studies naming them as principal investigator received $290,080 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,399 172
2024 General $38,395 182
2023 General $44,331 137
2022 General $77,730 179
2021 General $70,816 213
2020 General $65,986 194
2020 Research $1,685 1
2019 General $113,838 262

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rakesh Ranjan
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Rakesh Ranjan were reported at $12,399. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Rakesh Ranjan Psychiatry median Middle half National median
2019 $113,838 $184 $59–$605 $163
2020 $65,986 $119 $36–$372 $114
2021 $70,816 $143 $43–$576 $132
2022 $77,730 $153 $50–$590 $149
2023 $44,331 $170 $56–$651 $160
2024 $38,395 $179 $57–$673 $164
2025 $12,399 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $188,972 300 payments
  2. Otsuka America Pharmaceutical, Inc. $81,433 281 payments
  3. Alkermes, Inc. $75,184 187 payments
  4. Allergan Inc. $52,737 101 payments
  5. AbbVie, Inc. $12,781 94 payments
  6. Biogen, Inc. $4,912 1 payment
  7. Indivior Inc. $1,918 27 payments
  8. Vanda Pharmaceuticals Inc. $1,041 74 payments
  9. Lundbeck LLC $983 69 payments
  10. Janssen Pharmaceuticals, Inc $691 41 payments
  11. Other $2,844 164 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $322,037 132 payments
  2. Travel and Lodging $40,930 80 payments
  3. Consulting Fee $34,378 9 payments
  4. Food and Beverage $25,236 1,083 payments
  5. Education $907 28 payments
  6. Gift $8 7 payments
Products named General payments · program years 2019–2025
  1. AUSTEDO $122,468 169 payments
  2. ABILIFY MAINTENA $64,847 149 payments
  3. VRAYLAR $52,732 112 payments
  4. Austedo XR $48,297 83 payments
  5. ARISTADA Cns $45,043 143 payments
  6. ARISTADA Cns $45,043 143 payments
  7. ARISTADA Cns $44,767 122 payments
  8. ARISTADA Cns $44,767 122 payments
  9. ARISTADA INITIO $44,400 113 payments
  10. LYBALVI $30,932 85 payments
  11. Other $154,650 867 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. ACADIA Pharmaceuticals Inc $1,685 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

89

Median for Psychiatry: 574

Drug cost

$1,453

Median for Psychiatry: $27,624

Branded share of claims

12.4%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ziprasidone Hcl Generic 20 $861
Donepezil Hcl Generic 13 $312
Mirtazapine Generic 11 $162
Sertraline Hcl Generic 17 $68
Bupropion Xl Bupropion Hcl Brand 11 $48
Clonazepam Generic 17 $2

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Austedo XR
$27,895 — —
UZEDY
$7,483 — —
ABILIFY ASIMTUFII
$717 — —
ABILIFY MAINTENA
$586 — —
VRAYLAR
$369 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

1,340 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record